ストックスクリーナーアプリを入手
26.29
0.61%
0.16
前日終値:
$26.13
開ける：
$26.39
24時間の取引高:
219.57K
Relative Volume:
0.52
時価総額：
$485.66M
収益：
$294.28M
当期純損益:
$367.02M
株価収益率:
1.3902
EPS:
18.9115
ネットキャッシュフロー:
$75.66M
1週間 パフォーマンス:
+3.34%
1か月 パフォーマンス:
-24.06%
6か月 パフォーマンス:
-8.40%
1年 パフォーマンス:
+39.03%
1日の値動き範囲:
$26.18
$26.84
1週間の範囲:
$24.95
$27.05
52週間の値動き範囲:
$15.50
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
名前
Rigel Pharmaceuticals
セクター
電話
650-624-1100
住所
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
26.29 | 485.66M | 294.28M | 367.02M | 75.66M | 18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-05 | アップグレード | Jefferies | Hold → Buy |
| 2023-04-03 | 再開されました | Piper Sandler | Neutral |
| 2022-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-06-08 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 開始されました | B. Riley Securities | Neutral |
| 2020-11-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 再開されました | JP Morgan | Overweight |
| 2019-03-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 開始されました | Citigroup | Buy |
| 2018-05-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 再開されました | Piper Jaffray | Overweight |
| 2017-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 再開されました | H.C. Wainwright | Buy |
| 2017-03-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | 繰り返されました | Piper Jaffray | Overweight |
| 2016-07-13 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-13 | 開始されました | Piper Jaffray | Overweight |
| 2016-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 繰り返されました | Stifel | Buy |
| 2012-11-29 | 開始されました | UBS | Neutral |
| 2012-11-06 | 繰り返されました | Oppenheimer | Outperform |
| 2012-03-26 | 開始されました | Canaccord Genuity | Hold |
| 2010-12-10 | ダウングレード | MP Advisors | Outperform → Market Perform |
すべてを表示
Rigel Pharmaceuticals (RIGL) 最新ニュース
Rigel Pharmaceuticals (RIGL) Q4 earnings miss estimates - MSN
Rigel Pharmaceuticals Q4 2025 earnings preview - MSN
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors - TipRanks
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure - Fierce Biotech
Rigel Pharmaceuticals shows rising relative strength; still shy of key benchmark - MSN
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Rigel enrols first subject in R289 Phase Ib expansion for MDS - MSN
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update - Quantisnow
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential? - MSN
Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats - MSN
RIGL stock rises 59% in a year: Time to buy, hold or sell? - MSN
Rigel Pharmaceuticals: Growing Where It Matters (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL) earnings expected to grow: Should you buy? - MSN
Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results - Sahm
Analysts Set Expectations for RIGL Q3 Earnings - MarketBeat
Surging Earnings Estimates Signal Upside for Rigel (RIGL) Stock - MSN
Rigel Pharmaceuticals (RIGL) EPS Spike On Non Cash Gains Challenges Bullish Narratives - Sahm
Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty - The Globe and Mail
Brokers Offer Predictions for RIGL Q1 Earnings - MarketBeat
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
Rigel Pharmaceuticals (RIGL) Projects Revenue Decline for 2026 - GuruFocus
Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap DownWhat's Next? - MarketBeat
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $71 - 富途牛牛
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights: Record Net Income and Strategic Growth Initiatives - GuruFocus
Rigel Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
How The Rigel Pharmaceuticals (RIGL) Story Is Shifting With New Targets And Pipeline Progress - Yahoo Finance
Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY2025 Earnings After the Bell — Here’s What to Expect - AlphaStreet
Cumberland (CPIX) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Rigel’s Q4 2025 shows robust growth - Investing.com
Earnings call transcript: Rigel’s Q4 2025 shows robust growth By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RIGL) 2026-03-03 - Seeking Alpha
RIGL: Record sales and net income in 2025, with strong growth outlook and pipeline progress for 2026 - TradingView
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates - Bitget
Rigel Pharma (RIGL) Earnings Call Transcript - AOL.com
Rigel Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Rigel Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rigel Pharmaceuticals Q4 Earnings, Revenue Rise; 2026 Revenue Outlook Set - marketscreener.com
Rigel Pharmaceuticals (RIGL) Projects FY26 Revenue Growth - GuruFocus
Earnings Summary: Rigel Pharmaceuticals Q4Rigel Pharmaceuticals (NASDAQ:RIGL) - Benzinga
Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Quarterly Earnings Results, Misses Estimates By $0.19 EPS - MarketBeat
RIGL: Record 2025 revenue and net income, with 2026 outlook for continued growth and pipeline progress - TradingView
Rigel Pharmaceuticals reports Q4 EPS $13.54 with items, consensus $1.20 - TipRanks
Rigel (NASDAQ: RIGL) boosts blood cancer drug sales and advances pipeline - Stock Titan
Rigel: Q4 Earnings Snapshot - marketscreener.com
RIGL: Record 2025 revenue and net income, strong product growth, and positive 2026 outlook - TradingView
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Rigel Pharmaceuticals (RIGL) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):